Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CANFNASDAQ:CNATNASDAQ:RDHLNASDAQ:RSLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCANFCan-Fite BioPharma$1.06+1.0%$1.12$0.98▼$4.69$3.75M1.12238,934 shs78,557 shsCNATConatus Pharmaceuticals$0.00-60.0%$1.00$0.23▼$1.07$13K1.841.28 million shs204 shsRDHLRedhill Biopharma$1.84+4.1%$2.00$1.71▼$20.28$4.22M4.22163,648 shs10,888 shsRSLSReShape Lifesciences$2.56-4.1%$6.46$2.23▼$414.99$6.11M1.28769,718 shs243,682 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCANFCan-Fite BioPharma0.00%-1.85%+0.47%-33.75%-61.17%CNATConatus Pharmaceuticals-60.00%-63.64%-98.71%-98.71%-99.88%RDHLRedhill Biopharma0.00%-5.15%-3.16%-38.46%-99.25%RSLSReShape Lifesciences0.00%-17.68%-56.76%-84.58%-99.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCANFCan-Fite BioPharma2.9297 of 5 stars3.75.00.00.01.20.01.3CNATConatus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ARDHLRedhill BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ARSLSReShape Lifesciences0.558 of 5 stars0.05.00.00.01.90.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCANFCan-Fite BioPharma 3.33Buy$14.001,220.75% UpsideCNATConatus Pharmaceuticals 0.00N/AN/AN/ARDHLRedhill Biopharma 0.00N/AN/AN/ARSLSReShape Lifesciences 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest CNAT, RSLS, CANF, and RDHL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2025CANFCan-Fite BioPharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCANFCan-Fite BioPharma$674K5.57N/AN/A$1.76 per share0.60CNATConatus Pharmaceuticals$21.72M0.00N/AN/A$0.53 per share0.00RDHLRedhill Biopharma$8.04M0.52N/AN/A($3.66) per share-0.50RSLSReShape Lifesciences$8.01M0.76N/AN/A($8.66) per share-0.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCANFCan-Fite BioPharma-$7.63M-$1.79N/AN/AN/AN/AN/AN/AN/ACNATConatus Pharmaceuticals-$11.39MN/AN/A∞N/A-52.42%-48.22%-39.32%N/ARDHLRedhill Biopharma-$8.27MN/A0.00∞N/AN/AN/AN/AN/ARSLSReShape Lifesciences-$7.13M-$193.23N/A∞N/A-48.26%-251.90%-59.49%8/12/2025 (Estimated)Latest CNAT, RSLS, CANF, and RDHL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025RSLSReShape LifesciencesN/A$18.98N/A$18.98N/A$1.11 million4/4/2025Q4 2024RSLSReShape Lifesciences-$101.50-$47.25+$54.25-$1.89$3.17 million$1.81 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCANFCan-Fite BioPharmaN/AN/AN/AN/AN/ACNATConatus PharmaceuticalsN/AN/AN/AN/AN/ARDHLRedhill BiopharmaN/AN/AN/AN/AN/ARSLSReShape LifesciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCANFCan-Fite BioPharmaN/A2.93N/ACNATConatus PharmaceuticalsN/A16.2816.28RDHLRedhill BiopharmaN/A0.540.37RSLSReShape LifesciencesN/A1.530.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCANFCan-Fite BioPharma21.00%CNATConatus Pharmaceuticals15.20%RDHLRedhill Biopharma7.20%RSLSReShape Lifesciences22.06%Insider OwnershipCompanyInsider OwnershipCANFCan-Fite BioPharma0.80%CNATConatus Pharmaceuticals11.30%RDHLRedhill Biopharma6.81%RSLSReShape Lifesciences0.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCANFCan-Fite BioPharma83.54 millionN/ANot OptionableCNATConatus Pharmaceuticals3033.17 millionN/ANot OptionableRDHLRedhill Biopharma2102.29 million2.14 millionNo DataRSLSReShape Lifesciences502.39 million2.39 millionNot OptionableCNAT, RSLS, CANF, and RDHL HeadlinesRecent News About These CompaniesReShape Lifesciences Raises Equity to Avoid DelistingJune 18 at 6:29 PM | tipranks.comReShape Lifesciences Stock Soars On Distribution Agreement With Recon Supply, Draws Retail ApplauseJune 13, 2025 | msn.comReShape Lifesciences Inc: ReShape Lifesciences Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD MarketsJune 12, 2025 | finanznachrichten.deReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD MarketsJune 12, 2025 | globenewswire.comReShape Lifesciences® Announces Pricing of Public Offering of Common Stock Raising Approximately $2.6 MillionJune 11, 2025 | nasdaq.comReShape Lifesciences Stock Slumps As Company Prices Public Offering At Significant Discount: Retail Holds On To OptimismJune 10, 2025 | msn.comReShape Lifesciences® Announces Pricing of $2.6 Million Public OfferingJune 9, 2025 | globenewswire.comReShape Lifesciences Stock Soars On Regulatory Certification For Medical Devices In EU, UK: Retail Eyes Fair ValuationJune 4, 2025 | msn.comReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product PortfolioJune 3, 2025 | globenewswire.comReShape Lifesciences announces merger progressMay 30, 2025 | uk.investing.comReShape Lifesciences Inc. Reports First Quarter 2025 Financial Results and Strategic UpdatesMay 21, 2025 | quiverquant.comReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate UpdateMay 21, 2025 | globenewswire.comReShape Lifesciences Inc: ReShape Lifesciences Announces 1-for-25 Reverse Stock SplitMay 7, 2025 | finanznachrichten.deReShape Lifesciences Announces 1-for-25 Reverse Stock SplitMay 7, 2025 | globenewswire.comStocktwits Spotlight: NRx, CVS, ReShape Lead Weekly Jump In Health Care Stock ChatterMay 5, 2025 | msn.comPRISM Mid-Day Movers: Weight Loss Index Gains on Positive Data, Biotech Slumps on Disappointing ResultsMay 3, 2025 | theglobeandmail.comReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation SymposiumMay 2, 2025 | globenewswire.comReShape Lifesciences amends asset purchase terms with NinjourApril 30, 2025 | investing.comReShape Lifesciences Inc: ReShape Lifesciences Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon SystemApril 28, 2025 | finanznachrichten.deReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon SystemApril 28, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCNAT, RSLS, CANF, and RDHL Company DescriptionsCan-Fite BioPharma NYSE:CANF$1.06 +0.01 (+0.95%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.07 +0.01 (+0.57%) As of 06/18/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.Conatus Pharmaceuticals NASDAQ:CNATConatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.Redhill Biopharma NASDAQ:RDHL$1.84 +0.07 (+4.15%) Closing price 06/18/2025 03:59 PM EasternExtended Trading$1.82 -0.02 (-0.82%) As of 06/18/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.ReShape Lifesciences NASDAQ:RSLS$2.56 -0.11 (-4.12%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$2.55 -0.01 (-0.39%) As of 06/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
